Navigation Links
Clinical Trials, New Orders, Improved Services, and Approvals - Research Report on CareFusion, St. Jude Medical, Community Health Systems, Neurocrine Biosciences, and Alnylam Pharmaceuticals
Date:9/3/2013

/p>

On August 28, 2013, Alnylam Pharmaceuticals Inc. (Alnylam) announced the publication of complete study results from Phase I trials with ALN-TTR0a and ALN-TTR02 in a article titled "Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis" in the New England Journal of Medicine. Alnylam informed that the article shows that RNAi therapeutics targeting transthyretin (TTR) achieved rapid, dose-dependent, durable, and specific knockdown of the TTR, the disease causing protein in the TTR mediated amyloidosis (ATTR). Akshay Vaishnaw, M.D., Ph.D., Executive Vice President and Chief Medical Officer of Alnylam, said, "The Phase I studies of ALN-TTR01 and ALN-TTR02 demonstrate key human proof of concept for RNAi therapeutics targeting TTR but also for liver-expressed target genes in general, and we are thrilled to be publishing these landmark data in the New England Journal of Medicine. Notably, this is the first time that clinical results with an RNAi therapeutic have been published in the Journal, and we are proud to be associated with this milestone as we lead the clinical translation of RNAi therapeutics as a whole new class of innovative medicines." The Full Research Report on Alnylam Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/5b29_ALNY]

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for
    '/>"/>

SOURCE Analysts' Corner
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Arena Pharmaceuticals Completes Phase 1b Clinical Trial Evaluating APD811 for Pulmonary Arterial Hypertension
2. Magellan Diagnostics Receives FDA Clearance for LeadCare Ultra Bench-top Clinical Lead Analyzer
3. Cellular Biomedicine Group Announces Completion of Patient Enrollment for Phase I Clinical Trial for Liver Cancer
4. Selexys Pharmaceuticals Initiates SUSTAIN Phase 2 Clinical Trial in Sickle Cell Patients with Pain Crises
5. Final Patient Completes Prosonix Phase 2 Clinical Study with PSX1002 in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
6. Ampio Pharmaceuticals, Inc. Announces Positive Results for Ampion in Osteoarthritis of the Knee Clinical Trial
7. Start-up Seeks Crowd Funding to Complete Clinical Studies Supporting Breakthrough Blood Test for Earlier Detection of Melanoma
8. MacroGenics Appoints Jon Wigginton, M.D., as Senior Vice President, Clinical Development
9. Neuralstem Reports Second Quarter Financial Results And Provides Business And Clinical Update
10. Sanarias Malaria Vaccine Yields Unprecedented Protection In Phase 1 Clinical Trial
11. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for Second Quarter 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2015 Tumultuous market conditions – including changes ... M&A activity – have led more than half of ... sales reps. This marks the first time that the ... halfway point, according to the spring 2015 AccessMonitor™ ... ZS . AccessMonitor™ aggregates sales-call ...
(Date:9/2/2015)... 2, 2015 On Tuesday, September ... of physicians who prescribe biologics – Alliance ... Endocrinologists, American College of Rheumatology, Biologics Prescribers ... North American Society for Pediatric Gastroenterology, Hepatology ... Centers for Medicare and Medicaid Services (CMS) ...
(Date:9/2/2015)... , Sept. 2, 2015   Americord Registry , a ... placenta tissue banking company, announced today that is ... 500. Logo - http://photos.prnewswire.com/prnh/20150902/263095LOGO ... to have grown at least tenfold over the past three ... has continued this trend with 50% quarterly growth during the ...
Breaking Medicine Technology:Crossing the threshold: More than half of physicians restrict access to sales reps 2Crossing the threshold: More than half of physicians restrict access to sales reps 3Crossing the threshold: More than half of physicians restrict access to sales reps 4Crossing the threshold: More than half of physicians restrict access to sales reps 5Physician Groups Urge CMS: Follow FDA Lead on Unique Names for Biological Medicines 2Physician Groups Urge CMS: Follow FDA Lead on Unique Names for Biological Medicines 3Physician Groups Urge CMS: Follow FDA Lead on Unique Names for Biological Medicines 4Physician Groups Urge CMS: Follow FDA Lead on Unique Names for Biological Medicines 5Physician Groups Urge CMS: Follow FDA Lead on Unique Names for Biological Medicines 6Americord Registry Announces Ranking on 2015 Inc. 500 2
... LAKE FOREST, Ill., April 1, 2011 ... leading provider of clinical information and medication delivery technologies, ... clinical surveillance system , used by hospitals to help ... healthcare-associated infections (HAIs). The enhanced TheraDoc system includes new ...
... CHARLOTTE, N.C., April 1, 2011 Lance® Sandwich ... (JDRF) to support the organization,s efforts to find better ... Type 1 diabetes is an autoimmune disease that can ... to produce the insulin needed to turn food into energy. ...
Cached Medicine Technology:Hospira Launches Enhanced TheraDoc™ Clinical Surveillance System to Support Patient Safety and Help Improve Care 2Hospira Launches Enhanced TheraDoc™ Clinical Surveillance System to Support Patient Safety and Help Improve Care 3Lance® Joins JDRF in the Fight Against Type 1 Diabetes 2Lance® Joins JDRF in the Fight Against Type 1 Diabetes 3
(Date:9/2/2015)... ... September 02, 2015 , ... The Hydration ... allopathic medicine, opens its second location this week at 31542 S. Coast Hwy, ... feet of lounge space for patients to relax while receiving safe and effective ...
(Date:9/2/2015)... Burnsville, MN (PRWEB) , ... September 02, 2015 , ... ... forward to it; others dread it. However, few are prepared to face the academic ... once school starts. Our schools haven’t prepared them since schools don’t teach students how ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... the upper extremity surgical market, announced today that more than 600 successful patient ... in the hand. Plus, nearly 70 of these procedures have been on ...
(Date:9/2/2015)... ... September 02, 2015 , ... Lakeview Health, a nationally recognized ... Overdose Awareness Day. The goal is to provide people information regarding drugs and ... they may get help. , Lakeview Health will be publishing information ...
(Date:9/2/2015)... PA (PRWEB) , ... September 02, 2015 , ... Pentec ... prestigious 2015 Inc. 5000 List for an impressive sixth consecutive year. Less than 5 ... with only twelve firms in the “health” sector. Pentec’s 3-year revenue growth rate ...
Breaking Medicine News(10 mins):Health News:The Hydration Room Opens New Location In Laguna Beach, California 2Health News:The Hydration Room Opens New Location In Laguna Beach, California 3Health News:The Hydration Room Opens New Location In Laguna Beach, California 4Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 2Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 3Health News:Trigger Tome Surpasses 600 Successful Patient Procedures 2Health News:August 31 is International Overdose Awareness Day – Lakeview Health to Help Bring Awareness 2Health News:Pentec Health Once Again Named One of the Fastest-Growing Private Companies in America 2
... Tenn., Jan. 13 The National Eczema Association,(NEA) awarded ... Lotion. , The NEA Seal ... Education (EASE) program, which is intended to improve the,quality ... eczema and sensitive,skin. , "These ...
... now open for a more rewarding challenge , ... Jenkintown, PA (PRWEB) January 13, 2009 ... resolutions and according to USA.gov, losing weight and getting fit are among the ... many of those eager to fulfill their vows is to lace up their ...
... to meet their customers, product needs quickly and efficiently, Nationwide Medical/Surgical ... 2009-2010 season beginning in August. , ... (Vocus) January ... the Flu Vaccine for the 2009-2010 flu season. ...
... persistence to seek out the best treatment options available ... leg today. Bill,s proactive efforts led him to revolutionary ... Methodist Hospital, in Columbus, Ohio, where a team of ... During the minimally invasive procedure, they also found and ...
... announces the launch of their new website www.GlaceComplete.com . ... to Glenwood Systems and the company,s turbo-charged practice management/billing system GlaceComplete ... information. , ... Waterbury, CT (PRWEB) January Monday 12, ...
... of the 21,000 Americans who die each year of ... likely cause. So, the American Association of ... Cancer Survivors Against Radon (CanSAR) with a ... those who never smoked. Those making the connection, along ...
Cached Medicine News:Health News:National Eczema Association Anoints Theraplex Child-Friendly Eczema Products with Seal of Acceptance 2Health News:The Breast Cancer 3-Day Challenges Americans to Get Out of the New Year's Resolution Rut 2Health News:The Breast Cancer 3-Day Challenges Americans to Get Out of the New Year's Resolution Rut 3Health News:The Breast Cancer 3-Day Challenges Americans to Get Out of the New Year's Resolution Rut 4Health News:Nationwide Medical/Surgical Announces They Will Carry Flu Vaccine 2Health News:Irishman with Peripheral Arterial Disease (P.A.D.) Finds Leg-, Life-Saving Treatment In Columbus, Ohio 2Health News:Irishman with Peripheral Arterial Disease (P.A.D.) Finds Leg-, Life-Saving Treatment In Columbus, Ohio 3Health News:Irishman with Peripheral Arterial Disease (P.A.D.) Finds Leg-, Life-Saving Treatment In Columbus, Ohio 4Health News:Glenwood Systems, LLC Launches New Website -- GlaceComplete.com 2Health News:Program to Identify Likely Victims of Radon-Related Lung Cancer; Survivors Commit to Risk Reduction Despite Failed Government Policy 2Health News:Program to Identify Likely Victims of Radon-Related Lung Cancer; Survivors Commit to Risk Reduction Despite Failed Government Policy 3Health News:Program to Identify Likely Victims of Radon-Related Lung Cancer; Survivors Commit to Risk Reduction Despite Failed Government Policy 4
... protein 4 (IGFBP-4) is a 24 kDa protein ... IGF-I and IGF-II. It is also present in ... 28 kDa. IGFBP-4 has been identified in all ... types, including fibroblasts, neuroblastoma, prostate and bone cells ...
... the adrenal gland and gonads, is the ... both of which may be subsequently converted ... activity, estimated at ~(less than or equal ... androstenedione levels often exceed testosterone in both ...
... Inhibins are heterodimeric proteins that suppress ... from the pituitary. Inhibin consists of two ... linked together. Inhibin A consists of the ... the alpha-subunit and betaB-subunit. Only the dimeric ...
... a 7.5 kDa peptide which is secreted primarily ... mitogenic and metabolic actions involved in cellular growth. ... to target cell receptors. IGF-II binds with high ... monomeric protein which also serves as the receptor ...
Medicine Products: